Introduction {#s1}
============

Hyperglycaemia is frequent at admission in patients with and without diabetes mellitus (DM) \[[@C1]\]. It may be secondary to DM (diagnosed or undiagnosed) or stress. Stress-induced hyperglycaemia is a result of an increase in catecholamines, glucagon, growth hormone, proinflammatory cytokines and increased peripheral insulin resistance in response to physiological stress \[[@C2]\]. Systemic bacterial and viral infections are potent triggers of stress hyperglycaemia and this may also be the case for pneumonia.

Community-acquired pneumonia (CAP) remains a leading cause of hospitalisation and mortality worldwide \[[@C3], [@C4]\]. The incidence of hospitalisations caused by pneumonia has increased steadily worldwide \[[@C5]\]. Rates in Denmark have increased from 288 to 809 per 100 000 person-years over recent decades \[[@C6]\]. Previous studies have suggested that hyperglycaemia may be associated with severe outcome in a range of conditions, including sepsis \[[@C1], [@C7], [@C8]\]. In some CAP studies, an association with higher mortality has also been reported \[[@C9]--[@C12]\], while others have shown no association \[[@C13], [@C14]\]. Most studies have focused on the association between hyperglycaemia and long-term mortality (28--90 day mortality) after an episode of CAP \[[@C10], [@C13]\]. Thus, there is a need for further analysis on the impact of hyperglycaemia on morbidity and mortality associated with CAP, and particularly in-hospital mortality.

The main objective of the present study was to determine the impact of blood glucose levels on severe outcomes of CAP, defined as admission to an intensive care unit (ICU) and in-hospital mortality. Secondarily, we aimed to determine the impact of blood glucose levels on the clinical course of CAP.

Methods {#s2}
=======

Study population {#s2a}
----------------

We retrospectively included adult patients admitted to three Danish hospitals (one teaching and two smaller referral hospitals) in the CAP-NORTH cohort. This cohort has been described in detail elsewhere \[[@C15]\]. In brief, data were collected between January 1, 2011 and June 30, 2012. The hospitals served a population of approximately 360 000 citizens. The hospitals received all patients in need of acute hospital admittance because of the free access to treatment in public hospitals and absence of private medical emergency hospitals. Thus the study covered all patients residing in the catchment area of these hospitals. Patients admitted with pneumonia were identified based on the International Classification of Diseases 10th revision (ICD-10) codes noted at discharge. All patients who had one of the following ICD-10 codes either as primary or secondary diagnosis were evaluated for inclusion: pneumonia J10.0, J11.0 and J12.x--J18.x, J69.x, *Mycoplasma pneumoniae* B96.0, *Klebsiella pneumoniae* B96.1, Ornithosis A70.x and Legionellosis A481.

Patient files were reviewed to assess whether the study inclusion and exclusion criteria were fulfilled ([table 1](#TB1){ref-type="table"}). In brief, CAP was considered in patients with symptoms of lower respiratory tract infection, a new infiltrate on chest radiography and no hospital admission within the last 28 days. Each patient could only be included once into the study and was registered at their first presentation with CAP \[[@C15]\]. Information on DM was retrieved from the patient files and the patients were categorised as DM if 1) DM was self-reported, 2) the attending physician stated that the patient had DM or 3) the patient received either oral or injectable anti-diabetes medication before admission.

###### 

Inclusion and exclusion criteria

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Inclusion criteria**                                                             **Exclusion criteria**
  ---------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------
  **Age ≥18 years**\                                                                 **Hospital admission within the last 28 days prior to admission due to pneumonia**\
  **New infiltrate on chest radiography (confirmed by radiologist)**\                **Active tuberculosis**\
  **At least one of the following symptoms of lower respiratory tract infection**\   **Missing information on prior medical history**\
   Cough\                                                                            **Immunosuppression, defined as**\
   Purulent expectoration\                                                            Treatment with corticosteroids (≥20 mg prednisolone-equivalent/day \>14 days)\
   Fever ≥38.3 °C (rectal) or ≥37.8 °C (ear)\                                         HIV infection\
   Pathological lung auscultation                                                     Received cancer chemotherapy within the last 28 days and had neutropenia (neutrophil granulocytes \<1000 µL^−1^)\
                                                                                      Immunosuppression after organ or bone marrow transplantation

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data collection {#s2b}
---------------

Baseline characteristics, comorbidity and clinical findings at admission were collected from patient files. Data were entered into the CAPNETZ database ([www.capnetz.de](www.capnetz.de)) as well as into EpiData Entry 3.1 ([www.epidata.dk](www.epidata.dk)). Data related to hospitalisation were collected, including the use of antibiotics, microbiological findings and length of hospital stay (LOS). Duration of antibiotic therapy included hospitalisation and discharge.

Treatment length was registered as total length of antibiotic treatment (LOAB) and length of intravenous antibiotic treatment (LOIVAB). LOAB, LOIVAB and LOS were used as markers of the clinical course of CAP. As markers of severe outcome of CAP we considered admittance to intensive care unit (ICU) and/or death in hospital. Admission glucose was defined as the first measured glucose value on the admission day. We used CURB-65 as a severity score \[[@C16]\].

Except for comorbidities, data not mentioned/recorded in patients' files were noted as missing.

Ethics {#s2c}
------

The study was approved by the Danish Health and Medicines Authority (3-3013-340/1/) and the Danish Data Protection Agency (HIH-2013-017). Informed consent is not required under Danish legislation for register-based studies.

Statistics {#s2d}
----------

Data were analysed using SAS Enterprise Guide version 5.1 (SAS Institute A/S). Data were described as counts (%) for categorical variables and either means (standard deviation ([sd]{.smallcaps})) or medians (interquartile range (IQR)) for continuous variables as appropriate. The t-test, Wilcoxon rank sum test, χ^2^ and Fisher\'s exact test were used to test for differences between participants with and without DM, as appropriate. Where relevant, we adjusted for multiple comparisons using the Bonferroni correction. Patients who died in hospital were reported as having missing LOS.

Due to the skewed distribution, the clinical course outcome variables (LOIVAB, LOS and LOAB) were log-transformed (ln) and the proposed predictors, blood glucose levels and DM (DM *versus* non-DM) were assessed using a linear regression model. The association was assessed in univariate analyses and in a multivariate model to adjust for possible confounders. The regression coefficients were back-transformed (100%×(e^coefficient^−1), 95% CI 100%×(e^upper\ limit^−1) -- 100%×(e^lower\ limit^−1)) to provide percentage effects.

We used logistic regression analyses to assess the risk of severe outcome, which was defined as ICU admittance, in-hospital mortality or combined risk (ICU admittance and/or in-hospital mortality). Admittance blood glucose (continuous variable) was used to predict severe outcome and, because the impact of blood glucose levels may be affected by diabetes status, we tested for an interaction between blood glucose level and diabetes status. To adjust for confounding, relevant predictors (CURB-65, chronic obstructive pulmonary disease (COPD), heart diseases and chronic kidney disease) were adjusted for. Additionally, we assessed the association between pre-admission diabetes status (categorical variable) on the risk of a severe outcome in a similar model, unadjusted and adjusted. All statistical comparisons were two-sided and carried out at the 0.05 significance level.

Results {#s3}
=======

The CAP-NORTH cohort comprised 1320 patients with CAP \[[@C15]\], and data for 1318 patients were available for this study. Two patients were not included due to missing information on prior medical history. In total, 12.3% (162/1318) of patients were known to have DM at admittance ([table 2](#TB2){ref-type="table"}). There were no differences between patients with and without DM with respect to age, nursing home residency and smoking habits, but more patients with DM were male (64.2% *versus* 45.1%, p=0.001) and more often had chronic cardiac and kidney disease. Patients with DM were less likely to have received antibiotic treatment prior to admission (29.4% *versus* 37.6%, p=0.04). Patients with DM had higher median admittance blood glucose levels (9.2 mmol·L^−1^ *versus* 6.8 mmol·L^−1^ (mM), p\<0.001). 38% and 3% (p\<0.001) of patients with and without DM had admittance blood glucose ≥11.1 mM, respectively. At the time of admission, more patients with DM (63.4% *versus* 44.6%, p\<0.001) had signs of moderate to severe pneumonia according to CURB-65 ([table 2](#TB2){ref-type="table"}), predominantly due to age \>65 years and urea \>7.0 mM.

###### 

Characteristics of patients with and without diabetes mellitus at time of admission

                                             **Diabetes**     **Nondiabetes**   **p-value**
  ---------------------------------------- ----------------- ----------------- -------------
  **Patients**                                12.3 (162)        87.7 (1156)    
  **Demographic data**                                                         
   Age years                                  73 (65--80)       71 (58--82)        0.06
   Male                                       64.2 (104)        45.1 (521)         0.001
   Current smoker                              23.8 (35)        27.9 (295)         0.30
   Nursing home resident                       8.6 (14)         11.4 (131)         0.30
  **Comorbidities**                                                            
   Obstructive pulmonary disease               23.6 (38)        17.9 (205)         0.08
   Other pulmonary disease                     11.8 (19)        11.7 (135)         0.98
   Heart failure                               16.7 (27)         7.4 (86)         \<0.001
   Other cardiac disease                       27.2 (44)        14.1 (163)        \<0.001
   Liver disease                               0.62 (1)          0.95 (11)          1.0
   Kidney disease                              8.6 (14)          2.3 (27)         \<0.001
   Cerebrovascular disease                     13.0 (21)         9.9 (114)         0.22
   Other neurological disease                   1.9 (3)          4.3 (50)          0.13
   Malignancy                                  7.4 (12)          9.3 (107)         0.44
  **Admission blood glucose^\#^** **mM**    9.2 (7.3--13.5)   6.8 (6.0--7.9)      \<0.001
   Blood glucose ≤6 mM                         8.8 (14)         28.0 (317)      \<0.001^+^
   Blood glucose 6.1--11 mM                    52.8 (84)        68.8 (780)      \<0.001^+^
   Blood glucose ≥11.1 mM                      38.4 (61)         3.2 (36)       \<0.001^+^
  **CURB-65**                                                                  
   0--1                                        36.7 (51)        55.5 (553)      \<0.001^+^
   2                                           42.5 (59)        27.2 (271)      \<0.001^+^
   3--5                                        20.9 (29)        17.4 (173)        0.93^+^
  **CURB-65 parameters**                                                       
   Confusion                                   13.1 (21)        14.4 (162)         0.68
   Urea \>7.0 mM                               57.2 (91)        37.2 (424)        \<0.001
   Respiratory rate ≥30 min^−1^                16.3 (22)        10.9 (112)         0.11
   Blood pressure^¶^                           15.7 (25)        15.3 (172)         0.89
   Age ≥65 years                              77.2 (125)        56.2 (741)         0.001

Data are presented as % (n) or median (interquartile range). All variables had \<3% missing data except for current smokers (n=113, 8.5%) and CURB-65 (n=182, 13.8%). ^\#^: range 1.3--73.1 mM in diabetes patients and 3.2--21.2 mM in nondiabetes patients; ^¶^: systolic \<90 and/or diastolic ≤60 mmHg; ^+^: Bonferroni adjusted.

Association between admission blood glucose, DM and clinical course of CAP {#s3a}
--------------------------------------------------------------------------

We assessed whether the clinical course of CAP was different in patients with DM than in patients without DM, and found that LOS and LOIVAB for patients with DM were longer (6 days *versus* 5 days, p\<0.001; 4 days *versus* 3 days, p=0.01) ([table 3](#TB3){ref-type="table"}), whereas LOAB was similar in patients with and without DM (p=0.87). In order to adjust for potential confounders (CURB-65 score and comorbidities), we performed a linear regression analysis on log-transformed data, and found that LOS remained associated with DM, corresponding to a 22% (95% CI 5.15--41.37%) longer admission time compared to patients without DM. The association between DM and LOIVAB disappeared after adjusting (9%, 95% CI −5.27--26.20%).

###### 

Influence of diabetes mellitus on the clinical course of community-acquired pneumonia

                                           **Diabetes patients**   **Nondiabetes patients**   **p-value^\#^**
  --------------------------------------- ----------------------- -------------------------- -----------------
  **Patients**                                  12.3 (162)               87.7 (1156)         
  **Clinical course days median (IQR)**                                                      
   LOS^¶^                                        6 (4--10)                 5 (3--8)               \<0.001
   LOAB                                         10 (8--12)                10 (8--12)               0.87
   LOIVAB                                        4 (2--7)                  3 (2--6)                0.01
  **Severe outcome**                                                                         
   ICU admittance                                13.0 (21)                9.2 (106)                0.13
   In-hospital mortality                         10.5 (17)                 8.1 (94)                0.31
   Any severe event^+^                           19.8 (32)                13.9 (161)               0.05

Data are presented as % (n), unless otherwise stated. Missing information for length of antibiotic treatment (LOAB) and intravenous antibiotic treatment (LOIVAB) were 34 (2.5%) and 12 (0.9%) patients, respectively. IQR: interquartile range; LOS: length of stay; ICU: intensive care unit. ^\#^: LOS, use of antibiotics, need for ICU support and mortality were assessed in a univariate analysis stratified by diabetes; ^¶^: patients who died in hospital were counted as missing data (n=111, 8.4%); ^+^: in-hospital mortality and/or ICU admission.

Subsequently, we assessed the influence of admission blood glucose in an adjusted linear regression model and found that for each 1 mM increase in blood glucose, LOS increased by 2.8% (95% CI 0.70--4.25%) and the length of LOIVAB was extended by 1.4% (95% CI 0.03--3.01%). Blood glucose levels did not influence the LOAB.

Association between admission blood glucose levels and DM status and the risk of severe outcome {#s3b}
-----------------------------------------------------------------------------------------------

In total, 19.8% (32/162) patients with and 13.9% (161/1156) without DM had a severe outcome during hospital admission. This included admission to an ICU (13.0% *versus* 9.2%) and in-hospital death (10.5% *versus* 8.1%) ([table 3](#TB3){ref-type="table"}).

The difference between patients with and without DM with regard to overall risk of severe outcome (ICU and/or in-hospital death) was borderline significant (OR 1.52, 95% CI 0.998--2.32, p=0.051) by univariate analysis, whereas the differences in risk of either ICU admittance or death were not significant ([table 4](#TB4){ref-type="table"}).

###### 

Risk of severe outcome depending on diabetes status

                               **Crude analyses**   **Multivariate analyses^\#^**                      
  --------------------------- -------------------- ------------------------------- ------------------- ------
  **Any severe outcome^¶^**                                                                            
   Nondiabetes patients               Ref.                                                Ref.         
   Diabetes patients           1.52 (0.998--2.32)               0.051               1.43 (0.88--2.32)   0.15
  **ICU admission**                                                                                    
   Nondiabetes patients               Ref.                                                Ref.         
   Diabetes patients            1.48 (0.9--2.43)                0.13                1.62 (0.93--2.82)   0.09
  **In-hospital mortality**                                                                            
   Nondiabetes patients               Ref.                                                Ref.         
   Diabetes patients           1.33 (0.77--2.29)                0.31                0.92 (0.47--1.79)   0.80

ICU: intensive care unit. ^\#^: 1128 patients; adjusted for CURB-65, chronic obstructive pulmonary disease, heart disease and chronic kidney disease. ^¶^: in-hospital mortality and/or ICU admission.

By multivariate analysis adjusting for CURB-65 and comorbidity ([table 4](#TB4){ref-type="table"}), DM was no longer associated with any overall severe outcome (OR 1.43, 95% CI 0.88--2.31), in-hospital death (OR 0.92, 95% CI 0.47--1.79) or ICU admittance (OR 1.62, 95% CI 0.93--2.82).

We assessed the effect of blood glucose levels on severe outcome and found, in an unadjusted analysis, that the level of admittance blood glucose was associated with any severe outcome in both patients with and without DM. Specifically, for each 1 mM increase in glucose level, the OR for ICU admittance was 1.26 (95% CI 1.16--1.38) for patients without DM and 1.08 (95% CI 1.02--1.14) for patients with DM ([table 5](#TB5){ref-type="table"}). Adjustment for CURB-65 and comorbidity lowered the OR for patients with DM (OR 1.05, 95% CI 1.00--1.12), but not for patients without DM (OR 1.25, 95% CI 1.13--1.39).

###### 

Association between blood glucose levels and severe outcome in patients with and without diabetes mellitus

                                          **Crude analyses**   **Multivariate analyses^\#^**                      
  -------------------------------------- -------------------- ------------------------------- ------------------- ---------
  **Any severe outcome^¶^**                                                                                       
   Admission blood glucose per 1 mM^+^                                                                            
    Nondiabetes patients                  1.31 (1.21--1.43)               \<0.001              1.23 (1.12--1.35)   \<0.001
    Diabetes patients                     1.06 (1.004--1.11)               0.03                1.05 (0.99--1.11)    0.09
  **ICU admission**                                                                                               
   Admission blood glucose per 1 mM^+^                                                                            
    Nondiabetes patients                  1.26 (1.16--1.38)               \<0.001              1.25 (1.13--1.39)   \<0.001
    Diabetes patients                     1.08 (1.02--1.14)                0.01                1.05 (1.00--1.12)    0.07
  **In-hospital mortality**                                                                                       
   Admission blood glucose per 1 mM^+^                                                                            
    Nondiabetes patients                  1.24 (1.13--1.35)               \<0.001              1.10 (0.99--1.23)    0.09
    Diabetes patients                     1.04 (0.99--1.09)                0.15                1.05 (0.99--1.12)    0.11

ICU: intensive care unit. ^\#^: 1116 patients; adjusted for CURB-65, chronic obstructive pulmonary disease, heart disease and chronic kidney disease. ^¶^: in-hospital mortality and/or ICU admission. ^+^: stratified for diabetes status due to a strong interaction between diabetes status and blood glucose.

Similarly, elevated admission blood glucose was associated with increased in-hospital mortality (OR 1.24, 95% 1.13--1.35) in patients without DM, although this was partially confounded by CURB-65 and comorbidities (adjusted OR 1.10, 95% CI 0.99--1.23). Known diabetes did not seem to be associated with excess risk of mortality.

There was a strong interaction between DM status and blood glucose levels (test for interaction, p=0.01). This indicated that the association between blood glucose levels and ICU admittance depends on pre-admission DM status, and was more pronounced in patients without DM.

Discussion {#s4}
==========

We assessed the impact of blood glucose levels on severity of CAP. An increase in admission blood glucose was associated with a more severe outcome of CAP, predominantly in patients without DM. DM was not associated with in-hospital mortality or ICU admittance.

An increase in blood glucose at hospital admission was associated with prolonged LOS, LOIVAB and severe outcome (ICU and in-hospital mortality). Interestingly, the association between increasing blood glucose and LOS, LOIVAB and severe outcome was most pronounced for patients without DM. Diabetes was associated with prolonged LOS and LOIVAB, but only LOS remained significant after adjusting for confounders. Hyperglycaemia has been associated with excess mortality in patients admitted to ICUs \[[@C17]\] and in CAP patients with hyperglycaemia \[[@C9], [@C10], [@C18]\], although the literature is inconsistent \[[@C13], [@C14]\]. In 2012, L[epper]{.smallcaps} *et al.* \[[@C10]\] found, in a large prospective multicentre cohort study of CAP, that hyperglycaemia is strongly associated with 90 day mortality in patients without DM. The study by L[epper]{.smallcaps} *et al.* was a prospective study, where the patients were younger and one-third were not hospitalised. Despite differences in design and population, our study confirms this and other previous studies in showing that elevated blood glucose in patients without DM may be associated with severe outcome and mortality \[[@C9], [@C10], [@C18]\].

The association between an increase in admission blood glucose and a severe clinical course was most prominent in patients without DM. This is a somewhat counterintuitive finding, although the interaction between blood glucose and DM has been reported previously \[[@C10], [@C12], [@C19]\]. Explanations for the fact that hyperglycaemia in patients with DM apparently seemed less detrimental could be that patients with DM were more likely to have chronically elevated blood glucose levels than patients without DM. The stress hyperglycaemia response in patients with DM may therefore be overestimated due to higher glycaemic baseline levels compared to patients without DM. Moreover, clinicians may have had more focus on subsequent blood glucose regulation in patients with DM. However, it remains controversial whether tight glucose regulation is beneficial in the acute stages of diseases \[[@C20], [@C21]\].

In this cohort of hospitalised CAP patients, 12.3% had DM, which was comparable to recent studies of CAP, where the DM prevalence ranged from 9.8% to 21.4% \[[@C9], [@C10], [@C22], [@C23]\]. We did not find any association between DM and an increased risk of ICU admittance or in-hospital mortality, in spite of more severe disease at admittance based on the CURB-65 score. This is in contrast to previous studies reporting a higher mortality of patients with CAP and DM \[[@C9], [@C10], [@C24], [@C25]\]. We found comparable in-hospital mortality for patients with and without DM (10.5% and 8.1%, respectively) whereas L[epper]{.smallcaps} *et al.* \[[@C10]\] reported an increased 90 day mortality (14.5% *versus* 6%) while F[alguera]{.smallcaps} *et al.* \[[@C25]\] reported an increased 30 day mortality (17% *versus* 8%) of patients with DM compared to patients without DM. Mortality was similar in patients with and without DM at days 30 and 90 (11% and 15%, respectively) in our cohort \[[@C15]\].

The comparable mortality of patients with and without DM may be due to several factors. Firstly, all hospitalised patients were included, regardless of severity or mental status, including patients admitted to the ICU and those who died within the initial 24 h. These patients may be problematic to include in prospective studies due to difficulties in obtaining informed consent and a potential source of selection bias. Thus, patients included in our study were older and most likely more severely ill at admission, and the impact of DM was of minor importance compared to the overall severity.

Secondly, better overall management and earlier detection of patients with DM may result in lower than expected mortality from pneumonia. The age-standardised mortality rate among patients with DM in Denmark has been reduced by 22%, from 1.90 in 1997 to 1.49 in 2012 \[[@C26]\]. In this regard it would have been interesting to determine if differences in glycated haemoglobin (HbA~1c~) between the studies could confirm the hypothesis that better regulated DM patients had lower CAP-related mortality. These facts suggest that the excess mortality of pneumonia previously reported in diabetics is declining, while the average mortality in pneumonia is constant \[[@C6]\]. This may explain why we were not able to detect a difference in mortality between patients with and without DM.

Stress-induced hyperglycaemia is caused by a complex interplay of hormones such as catecholamines, growth hormone, cortisol and cytokines, which leads to excessive hepatic glucose production and insulin resistance \[[@C1]\]. Stress hyperglycaemia is mediated by greater inflammatory and neuroendocrine alterations than are expected in chronic hyperglycaemia, and some of these alterations might be subject for an intervention \[[@C1]\]. Microvascular endothelial dysfunction, *e.g.* as seen in multiorgan failure, has been associated with stress hyperglycaemia, and one study suggests that improved outcomes associated with intensive insulin therapy may in part be to endothelial protection \[[@C1], [@C27]\]. Our study does not allow any conclusions on the beneficial effects of glycaemic control during severe infections. Therefore, studies in a non-ICU setting are required to determine whether optimal regulation of blood glucose levels improves (at least in the short term) outcomes in CAP.

Limitations {#s4a}
-----------

Firstly, our study was retrospective and observational, and we were not able to determine any causality between hyperglycaemia and severe outcome, and we cannot exclude that there was residual confounding that was not accounted for. Secondly, relying on self-reported DM gives rise to the problem that a proportion of our patients might have had unrecognised DM. Determination of HbA1c levels on admission could have solved this problem, but this information was not available. Thirdly, we cannot exclude that our sample was too small and hence lacked the power to detect a difference in mortality between patients with and without DM. Fourthly, glucocorticoids may increase blood glucose levels \[[@C28]\]. Therapy with glucocorticoids of more than 20 mg daily for more than 14 days prior to admission was an exclusion criterion. Glucocorticoids are not recommended for CAP in Denmark. Only patients with suspicion of COPD exacerbations would have been offered prednisolone treatment for 10 days. We did not register the use of glucocorticoids during admission, but we did adjust our analysis for COPD. Fifthly, we did not register the time or nature of fluid resuscitation, which could have had an impact on blood glucose levels, and we did not have information on time from admission to antibiotic treatment. Sixthly, although our study in general had few missing values, nearly 14% of the patients were missing a CURB-65 score. Finally, some patients with CAP might have been missed if they were discharged with a diagnosis other than pneumonia.

Strengths {#s4b}
---------

Due to the multicentre design, data were available for the entire geographic region and we believe that the cohort was representative of patients hospitalised with CAP in economically developed countries. Secondly, we evaluated both the primary and secondary diagnosis of pneumonia. This ensured that no patients were excluded due to severe illness or atypical presentation of CAP. Thirdly, by applying our inclusion and exclusion criteria we eliminated the potential confounding of hospital-acquired pneumonia and excluded non-pneumonia patients. Finally, the study reflected "real life", with no excessive focus on study patients or adherence to specific treatment regimens. This may allow for careful generalisation of the results.

Conclusions {#s4c}
-----------

An increase in admission blood glucose was an important clinical indicator of CAP severity, preferentially among patients without DM, while DM did not affect the severity of CAP in terms of risk of ICU admittance or in-hospital mortality. In patients without DM, an increase in blood glucose was associated with a higher risk for ICU admittance and a tendency towards an association with in-hospital mortality in line with recent evidence.
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